Marinaro Michael sold $1.0M of MDT

Marinaro Michael (EVP, Pres MedSurg and Americas) sold 10,420 shares of Medtronic plc (MDT) at $96.00 ($1.00M total) on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Marinaro Michael
Published Oct 16, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDT
Bearish
high confidence
Mentioned
$MDT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDTBearishLow
01

Why it matters

The disclosed sale adds a data point for traders monitoring insider activity; historically, such sales can precede short‑term price dips.

02

Market read

While the transaction is modest, it provides fresh insider information that may influence short‑term trading decisions.

03

What to watch

Potential upcoming earnings or product announcements could offset any negative sentiment from the sale.

Relevance 5/10Novelty 3/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions; this filing reports a $1M sale by a senior Medtronic executive.

Company-level read

Ticker impact

$MDTBearishHigh confidence
Context

EVP and Pres MedSurg Michael Marinaro sold 10,420 Medtronic shares for $1.0M via a Form 4 filing.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

C‑suite insider sales are watched by traders; a $1M sale is modest but may trigger short‑term downside bias.

Market effects

Minimal impact on the broader medical device sector; similar insider sales are routine.

Limited to U.S. investors tracking Medtronic; no broader regional effect.

Low global relevance; Medtronic is a large cap but the transaction size is small.

Counterpoint

The sale could be unrelated to company outlook; investors might view it as routine portfolio rebalancing.

Key entities

  • Medtronic plc

    Global medical device manufacturer (ticker MDT).

  • Marinaro Michael

    Executive Vice President, President MedSurg and Americas at Medtronic.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.